Generalized Lipodystrophy
1
Pipeline Programs
2
Companies
1
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
AP
Trial Timeline
Clinical trial activity over time
2025
2026
Amryt PharmaMetreleptin
Clinical Trials (1)
Total enrollment: 15 patients across 1 trials
Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy
Start: May 2025Est. completion: Sep 202615 patients
Phase 3Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 15 patients
2 companies competing in this space